US 12,280,026 B2
Use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease
Mark Williams, Winnipeg (CA)
Assigned to ALGERNON PHARMACEUTICALS INC., Vancouver (CA)
Appl. No. 17/255,364
Filed by ALGERNON PHARMACEUTICALS INC., Vancouver (CA)
PCT Filed Jun. 25, 2019, PCT No. PCT/CA2019/050881
§ 371(c)(1), (2) Date Dec. 22, 2020,
PCT Pub. No. WO2020/000092, PCT Pub. Date Jan. 2, 2020.
Claims priority of provisional application 62/809,330, filed on Feb. 22, 2019.
Claims priority of provisional application 62/690,738, filed on Jun. 27, 2018.
Prior Publication US 2021/0260000 A1, Aug. 26, 2021
Int. Cl. A61K 31/4741 (2006.01); A61K 31/136 (2006.01); A61K 31/167 (2006.01); A61K 31/4184 (2006.01); A61K 38/18 (2006.01); A61K 45/06 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/167 (2013.01) [A61K 31/136 (2013.01); A61K 31/4184 (2013.01); A61K 38/1816 (2013.01); A61K 45/06 (2013.01); A61P 13/12 (2018.01)] 8 Claims
OG exemplary drawing
 
1. A method for the treatment or prophylaxis of renal fibrosis or kidney disease in a subject, the method comprising administering:
a therapeutically effective amount of Repirinast to the subject.